ombitasvir/paritaprevir/ritonavir治疗基因型1b丙型肝炎患者的上市后监测:一项2期和3期临床试验的随访研究

{"title":"ombitasvir/paritaprevir/ritonavir治疗基因型1b丙型肝炎患者的上市后监测:一项2期和3期临床试验的随访研究","authors":"Tetsuro Shimakami, R. Sakuma, K. Kawana, Kaoru Ohchi, S. Mochida, H. Kumada","doi":"10.2957/kanzo.63.319","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Post-marketing surveillance of ombitasvir/paritaprevir/ritonavir for patients with hepatitis C virus genotype 1b infection: A follow-up study of phase 2 and 3 clinical trials\",\"authors\":\"Tetsuro Shimakami, R. Sakuma, K. Kawana, Kaoru Ohchi, S. Mochida, H. Kumada\",\"doi\":\"10.2957/kanzo.63.319\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":35810,\"journal\":{\"name\":\"Acta Hepatologica Japonica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Hepatologica Japonica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2957/kanzo.63.319\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Hepatologica Japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2957/kanzo.63.319","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}